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1. Introduction
Despite considerable research, the relationships between obesity and metabolic disorders have
yet to be fully understood. Recent evidence has revealed that fat depots, rather than the volume
of fat, are essential in determining systemic insulin sensitivity. Adipose tissue is classified into
visceral adipose tissue, including epididymal, mesenteric and perirenal fat, and subcutaneous
adipose tissue according to its anatomical location. Increases in visceral adipose tissue are
considered to be linked to insulin resistance [1, 2]. Especially, mesenteric fat is postulated to
relate more closely to metabolic disorders, as mesenteric fat secretes free fatty acids and other
substances directly into the portal vein [3]. Although the mechanisms regulating fat distribu‐
tion remain obscure, sex hormones are unquestionably one of the determinants.
Since men tend to accumulate much more visceral fat than women, androgens have been
postulated to promote insulin resistance. In practice, low serum testosterone levels promote
obesity. Numerous studies have demonstrated that androgen deprivation therapy (ADT)
increases the risk of obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease
in patients with prostate cancer [4-8]. Basaria et al, pointed out that high fat mass, as well as
low bone density and anemia, was observed in men with prostate cancer treated with ADT
compared with ones treated without it. They concluded that patients receiving ADT are at
enhanced risk for insulin resistance and cardiovascular disease. Katznelson et al, reported that
percent body fat was greater in acquired hypogonadal men compared with eugonadal
controls, which was improved by testosterone replacement therapy [9].
Recently, a high prevalence of hypogonadism in men with obesity, metabolic syndrome and
type 2 diabetes has been recognized. Dhindsa et al, reported that total testosterone and free
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
testosterone inversely relate to BMI and fat mass [10] in type 2 diabetic men. Kapoor et al, in a
cross-sectional study of 355 type 2 diabetic subjects, found overt and borderline hypogonadism
in 42%, with 42 of these men having free testosterone levels <0.255 nM [11]. Although the
Framingham Heart Study concluded that sex hormone-binding globulin (SHBG), but not
testosterone, is significantly associated with metabolic syndrome [12], both low SHBG and low
free testosterone may contribute to low serum total testosterone level in obese and diabetic
men [13]. Another issue currently of interest is whether low testosterone is a cause or result
[13, 14]. Weight loss induced by diet or surgery has been demonstrated to increase testosterone
level and sexual function [15-17]. Probably, low testosterone and metabolic disorders worsen
each other. The results of clinical studies of testosterone replacement therapy were reviewed
by Grossmann [13]. RTC was performed in 10 trials in obese men with borderline low
testosterone levels. Although reduced fat mass was commonly observed, improved insulin
sensitivity was detected in only 2 trials. Six RCTs in diabetic patients similarly demonstrated
beneficial changes in body composition. However, reduction of HOMA-R was detected in 3
trials, and decreased HbA1c in one. These data suggested the limited efficacy of testosterone
replacement. Although only one meta-analysis noted that combined prostate events including
prostate cancer, elevated PSA and prostate biopsies were more frequent in testosterone-treated
men [18], there is no clear evidence that testosterone replacement increases the incidence of
prostate cancer. However, the possibility remains that the study was too small to detect
significant results. In contrast, a significantly increased risk of cardiovascular events has been
associated with testosterone therapy [19, 20], emphasizing that its potential risks should not
be ignored.
Dehydroepiandrosterone (DHEA) and its sulfate ester, dehydroepiandrostrone-sulphate
(DHEA-S) are referred as a weak androgen produced in adrenal gland (90%) and testis (10%)
in men [21]. DHEA is an intermediate product, which is synthesized from pregnenolone, and
converted to testosterone and estrogen. DHEA is one of the most abundantly secreted steroids,
although its precise physiological roles remain uncertain. DHEA exerts 0.1-2% of the activity
of testosterone on the genital organs [22], and 42% on bone formation in mice [23]. Since no
specific nuclear receptor for DHEA or DHEA-S has been identified, these hormones are
regarded as precursors of more active androgens, such as testosterone and 5α-dihydrotestos‐
terone (DHT), or estrogens. In addition, DHEA and DHEA-S can be converted to more active
forms subcellularly in target tissues, the underlying mechanism of which was referred to as
“intracine” by Labrie [24].
Both serum DHEA and testosterone levels decline during the aging process [25, 26]. Hence,
low  serum  DHEA  level  has  been  assumed  to  be  involved  in  the  development  of  age-
related diseases and shortening of the life span. Such studies suggest an association between
high serum DHEA-S level and longevity. However, numerous studies have reported that
serum  DHEA(-S)  exhibits  positive,  negative  or  no  relation  to  adiposity,  cardiovascular
disease  and  mortality  in  men and women [27].  Recent  longitudinal  and  cross  sectional
studies support the favorable effects of DHEA-S on cardiovascular disease and all-cause
mortality in both sexes [28-30].
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Like the case of testosterone, inconsistent results of DHEA replacement have been published.
DHEA replacement decreased fat mass and elevated bone mineral density (BMD) [31],
whereas, opposite results were obtained [32] in elderly men and women with DHEA defi‐
ciency. Recently, Corona et al, conducted a meta-analysis study of 25 RTC trials of DHEA
supplementation in elderly men. They observed no significant effects on the levels of glucose,
insulin, total cholesterol or BMD with DHEA, while a small but significant reduction of fat
mass was detected in the supplemented group [33].
Production of testosterone in the testis is regulated by gonadotropin, while that of DHEA in
the adrenal gland is by ACTH. Low free testosterone is correlated positively with LH in diabetic
men, and therefore, hypogonadotropic hypogonadism is common in these patients [34].
However, the pathogenesis of low DHEA level has been unclear. Both serum testosterone and
DHEA levels decline with aging. Although some studies have published data on testosterone
and DHEA in elderly persons [35, 36], to our knowledge, no research has focused on individual
relationships among testosterone, DHEA and metabolic disorders. Theoretically, low testos‐
terone level might be compensated for by DHEA via an intracrine mechanism in men having
low testosterone and normal DHEA level. The opposite can also be supposed. Therefore, we
speculate that severe metabolic impairment might be observed in men with low testosterone
and low DHEA levels. Further study is necessary to help clarify this issue.
In animal studies, extensive research has elucidated the physiological and pharmacological
roles of androgens. However, few papers have compared testosterone and DHEA. The
hormonal actions of testosterone and DHEA are mediated via the androgen receptor (AR), and
so the difference in biological activity between these hormones may be caused by the efficacy
of steroid converting enzymes mediated by an intracrine mechanism. In addition, numerous
cell surface receptors for testosterone and DHEA have been identified [37, 38]. Differences in
the biological responses to testosterone and DHEA may be derived from these membrane
receptors. Anagnostopoulou et al, reported opposite effects of DHEA and testosterone on the
apoptosis of prostate and colon cancer [39]. They concluded that the differential effects of these
hormones on nerve growth factor receptors in cancer cells accounted for these results. Piñeiro
et al, showed that DHT, DHEA-S, stanozolol (non-aromatizable androgen), and androstene‐
dion, but not testosterone, suppressed leptin secretion in cultured adipocytes sampled from
female omental adipose tissue [40]. The authors presumed that aromatization of testosterone
might result in effects opposite to those of other androgens. Sato et al, considered that testos‐
terone increased the expression level of Glut4 more potently than DHEA in cultured skeletal
muscle, which was abrogated by a DHT inhibitor [41]. These results suggested that DHT, a
metabolite of testosterone and DHEA, finally acts as an androgen in skeletal muscle. In this
article, we outline our research investigating the impact of androgens, testosterone and DHEA,
on adiposity and glucose metabolism, and the results of our recent study.
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2. Materials and Methods
2.1. Animals
Male Wistar rats and C57/black mice at 8 wk of age were fed with or without (control)
0.4%  testosterone  or  0.4%  DHEA  containing  food  in  CE2  powder  (carbohydrate  51.4%,
protein  24.9%,  fat  4.6%,  fiber  3.7%)  for  4  wk.  Individual  food  consumption  was  deter‐
mined  by  subtracting  the  food  remaining  from  that  supplied  every  2-3  days,  with  the
averages  of  these  values  in  one  week  expressed  as  the  weekly  food  consumption.  The
animals were housed in a specific pathogen-free facility with a 12-h light/12-h dark cycle.
After sacrifice white adipose tissue (epididymal fat), skeletal muscle (gastrocnemius muscle)
brown adipose tissue (BAT) and liver were collected. All procedures for animal care were
carried out in accordance with protocols approved by the University of Gifu’s Institution‐
al Animal Care Committee.
O2 consumption (VO2), CO2 production (VCO2) and locomotor activity in mice were measured
individually by indirect calorimetry using an Oxymax apparatus (Columbus Instruments,
Columbus, OH) as described previously [42]. Respiratory exchange rate (RER) was calculated
as VCO2/VO2. Heat generation was calculated as caloric value (3.815+1.232 × RER) × VO2.
2.2. Cell culture
3T3-L1 preadipocytes were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.
Upon confluence, 3T3-L1 preadipocytes were differentiated with differentiation medium
containing insulin, dexamethasone and IBMX for 3 days followed by incubation with DMEM
again. At 5 days after the differentiation, cells were stimulated with 50 nM DHEA or 50 nM
testosterone for 48 hr. The content of triglyceride was visualized with Oil Red O (Santa Cruz
Biotechnology, Santa Cruz, CA) according to the manufacturer’s instruction.
F442A preadipocytes were cultured in DMEA with supplement as described above. When
confluence was reached (0d), 50 nM DHEA or testosterone was added to the medium to
evaluate the effects of these hormones on spontaneous differentiation of F442A cells into
mature adipocytes without differentiation medium.
C2C12 myoblasts were cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/
mL penicillin, and 0.1 mg/mL streptomycin. When cells reached 90% confluence, the medium
was exchanged for DMEM containing 4% horse serum (differentiation medium). After
incubation with the differentiation medium for 7 days, cells were morphologically determined
to complete the differentiation into C2C12 myotubes, and then these cells were treated with
various concentrations of testosterone for 48 hr
2.3. Real time PCR
Real time PCR was performed to measure mRNA expression levels of PPARγ, fatty acid
binding protein 4 (FABP4), lipoprotein lipase (LPL), adiponectin, SREBP-1, fatty acid synthase
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(FAS) and glyceraldehyde 3-phosphate dehydrogenase (G3PDH) in 3T3-L1 adipocytes, and
PGC1α, cytochrome C and G3PDH in C2C12 myotubes, as described previously [43-45]. All
data were normalized to the expression level of G3PDH.
2.4. Triglyceride content in liver and skeletal muscle
Liver and gastrocunemius muscle were homogenized in KRP buffer, and the triglyceride
in the homogenate was extracted with chloroform-methanol, and assayed using a LabAs‐
say  Triglyceride  kit  (Wako  Pure  Chemical  Industries,  Ltd,  Osaka,  Japan)  as  described
previously [43].
2.5. Western blot
The cell lysate was mixed with Laemmli sample buffer and boiled for 3 min. Equal amounts
of cell lysate were subjected to SDS-PAGE, and transferred onto nitrocellulose paper. The
paper was blocked with 1% BSA, and incubated with anti-PPARγ antibody, anti-adiponectin
antibody or anti-actin antibody (Santa Cruz). Protein bands were visualized with an ECL
system.
2.6. Statistics
All experimental results were calculated as means ± SE. Statistical comparisons were per‐
formed by Student’s t-test or ANOVA. Significance was defined as P < 0.05.
3. Results
3.1. Body weight and plasma glucose level
Treatment with testosterone or DHEA containing food reduced weight gain in both rats (Fig.
1A) and mice (Fig. 1B). Administration of testosterone and DHEA reduced body weight
equivalently. The dose response study showed that food containing both testosterone and
DHEA at 0.4% significantly suppressed body weight gain (Fig.1C). Our previous study [43]
indicated that treatment with 0.4% testosterone for 4 wk resulted in an increase of serum
testosterone and DHEA-S levels up to 674% and 1040%, respectively (note that serum DHEA-
S level is very low in rodents due to the lack of 17α hydroxylase in adrenal glands), whereas
treatment with DHEA increased testosterone and DHEA-S levels up to 310% and 6420%,
respectively. The fact that these androgens are convertible to each other, partially explains the
similar results obtained with administration of these hormones. Administration of testosterone
and DHEA did not influence fasting plasma glucose level in rats (Fig. 1D), while testosterone
suppressed it a little but significantly in mice (Fig. 1E). Food consumption was not influenced
by the administration of either hormone in rats (Fig. 1F).
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Figure 1. Effects of administration of DHEA and testosterone on body weight. Effects of treatment with 0.4% DHEA or
testosterone containing food for 4wk on body weight in Wistar rats (n=6) (A) and C56/black mice (n=4) (B) at 8 wk of
age are shown. *: p<0.05 vs control. Effects of 0.1%-0.4% DHEA or testosterone containing food for 4wk on body
weight in C57/black mice (n=4) (C) are shown. *: p<0.05 vs control. Effects of treatment with 0.4% DHEA or testoster‐
one containing food for 4wk on fasting plasma glucose level in Wistar rats (n=6) (D) and C56/black mice (n=4) (E) are
shown. *: p<0.05 vs control. Effects of DHEA or testosterone administration on food consumption in mice (n=4) are
shown. Black solid line: Control, Red broken line: DHEA, Blue broken line: testosterone. *: p<0.05 vs control.
3.2. Effect of DHEA and testosterone on adipocytes
Administration of DHEA or testosterone suppressed fat weight, including that of subcutane‐
ous, epididymal and mesenteric fat (Fig. 2A). In addition, both DHEA and testosterone
decreased adipocyte size equivalently (Fig. 2B). We found that treatment with DHEA reduced
the expression of PPARγ in adipocytes in both in vivo and in vitro [42]. Treatment with DHEA
and testosterone similarly reduced the expression level of PPARγ in adipose tissue isolated
from Wistar rats and 3T3-L1 adipocytes (Fig. 2C, D). Genes regulated by PPARγ, such as FABP
4, LPL and adiponectin were equally down-regulated by DHEA and testosterone in 3T3-L1
adipocytes. Neither hormone influenced the expression levels of genes, which are not directly
regulated by PPARγ, such as SREBP-1 and FAS (data not shown). Administration of DHEA
or testosterone decreased triglyceride content in liver and skeletal muscle to the same degree
in rats (Fig. 2 E, F).
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Figure 2. Effects of administration of DHEA and testosterone on adipocytes. Effects of treatment with DHEA or testos‐
terone for 4wk on fat weight (black: subcutaneous, green: epididymal, blue: mesenteric fat, n=6) (A), and histological
findings (B) are shown. *: p<0.05 vs each control. Effects of treatment with DHEA or testosterone on the protein level of
PPARγ and adiponectin in adipose tissue in Wistar rats were evaluated. A typical result was shown (C). Effects of
treatment with DHEA or testosterone on the expression of adipocyte specific genes in 3T3-L1 adipocytes are shown
(D). Fully differentiated 3T3-L1 adipocytes were incubated with 50 nM DHEA or testosterone for 48 hr. Expression lev‐
els of PPARγ (black), FABP4 (blue), LPL (red), adiponectin (green) were shown (n=6). *: p<0.05 vs each control. Effects
of treatment with DHEA or testosterone on triglyceride content in liver (n=5) (E) and skeletal muscle (n=5) (F) in Wistar
rats are presented. *:p<0.05 vs control.
Next, we examined the effects of these hormones on adipocyte differentiation. We observed
the differentiation of F442A cells, since they spontaneously differentiate into mature adipo‐
cytes when they reach confluence. DHEA and testosterone suppressed the accumulation of
triglyceride (Fig. 3A) and the appearance of PPARγ and FABP4 mRNA during the differen‐
tiation process. These data indicated that DHEA and testosterone similarly suppress adipocyte
differentiation.
3.3. Effect of DHEA and testosterone on mitochondrial biogenesis
As noted above, since the administration of neither DHEA nor testosterone influenced food
consumption, we speculated that these hormones elevate energy expenditure. Hence we
examined the effects of testosterone administration on energy production. Mice were treated
with or without testosterone for 4 wk, and then, oxygen consumption and locomotor activity
were measured by indirect calorimetry. O2 consumption and CO2 production were increased
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significantly in testosterone-treated mice, regardless of whether the values were normalized
by body weight or not (Fig. 4B-E). In addition, heat production, the values of which were
normalized by body weight, was elevated in testosterone-treated mice (Fig. 4G). No difference
was detected in respiratory exchange rate between control and testosterone-treated mice (Fig.
4H). To our surprise, administration of testosterone suppressed locomotor activity (Fig. 4I).
These results indicate that administration of testosterone increases the basal metabolic rate.
Therefore, we evaluated the effects of administration of these androgens on mitochondri‐
al biogenesis and its upstream regulator, PGC1α. Expression of mitochondrial protein, Cox4,
and PGC1α was elevated in skeletal  muscle,  but not brown BAT or liver,  isolated from
testosterone-treated rats (Fig. 5A). The increase of Cox4 in skeletal muscle induced by DHEA
administration  was  less  than  that  induced  by  testosterone  (Fig.  5B).  The  testosterone-
induced increases  in  mRNA levels  of  PGC1α and cytochrome C were  greater  than  the
DHEA-induced  ones  in  C2C12  myotubes  (Fig.  5C).  These  results  show  that  increased
mitochondrial  biogenesis  by  these  hormones  leads  to  up-regulation  of  energy  expendi‐
ture, which may result in reduced adiposity.
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Figure 3. Effect of treatment with DHEA and testosterone on the differentiation of F442A adipocytes. F442A preadipo‐
cytes were cultured in DMED. When cells reached confluence as judged by the morphological findings (0d), 50nM
DHEA or testosterone was added to the medium, followed by subsequent incubation for the indicated period. Trigly‐
ceride accumulation was assessed with oil-Red staining at 7d (A). Expression levels of PPARγ and FABP4 were meas‐
ured with real time PCR on the indicated day (n=4) (B). *:p<0.05 vs each control.
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Figure 4. Effects of treatment with testosterone on oxygen consumption, heat production and locomotor activity. C56/
black mice at 8 wk of age were treated with testosterone for 4 wk, and individual oxygen consumption and locomotor
activity were determined by indirect calorimetry (A). Cumulative O2 consumption for 24 hr (B) and normalized values
by body weight (C), CO2 production (D) and normalized values by body weight (E), heat production for 24 hr (F) and
normalized values by body weight (G) are shown. Values of RER (H) and locomotor activity (I) for 24 hr are also
shown. *: p<0.05 vs control, **: p<0.01 vs control
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Figure 5. Effect of treatment with DHEA and testosterone on mitochondrial biogenesis. Wistar rats were treated with
DHEA or testosterone for 4 wk. Effects of treatment with testosterone on the expression of PGC1α and Cox4 in skeletal
muscle, BAT and liver are shown (A). Typical results of western blot are shown in the left panel, and quantified results
are shown in the right (n=4). White: Control, Black: Testosterone-treated. *:p<0.05 vs control. Representative image of
immunohistochemistry of skeletal muscle isolated from control, DHEA-treated and testosterone-treated rats are shown
(B). Effects of incubation with 10 nM DHEA or testosterone for 48 hr on the expression of PGC1α and cytochrome C
mRNA in C2C12 myotubes (n-4) are shown (C). *: p<0.05 vs control, #: p<0.05 vs DHEA.
4. Discussion
Coleman et al., demonstrated that administration of DHEA reduces blood glucose level in db/
db mice [46]. We found that administration of DHEA improved blood glucose in OLETF rats,
a model of obese diabetes, but not GK rats, a model of lean diabetes [47]. Accordingly, we
presumed that DHEA-induced weight reduction might contribute to improving blood glucose
levels. Although administration of DHEA consistently suppresses body weight and fat weight,
significant improvement of blood glucose is detected only in extremely obese animals [44]. We
noted that DHEA and testosterone reduce the expression of PPARγ in adipocytes [43, 44].
Heterozygous PPARγ deficient mice are protected from insulin resistance under a high-fat
diet [48], and reduced receptor activity of PPARγ by Pro12Ala substitution leads to lower body
mass index in man [49], suggesting that modest suppression of PPARγ activity may help to
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prevent obesity and resultant insulin resistance. However, the production and secretion of
adiponectin are positively regulated by PPARγ in adipocytes [50], and inhibition of PPARγ
may result in insulin resistance due to low plasma adiponectin level. In this study, we showed
that DHEA and testosterone decrease PPARγ, as well as adiponectin (Fig. 2C, D). This result
is consistent with the fact that despite their obese phenotype, glucose homeostasis remained
intact because of a high plasma adiponectin level in androgen receptor null mice (ARKO) [51].
These data explain the results of the numerous clinical studies described above in which
administration of DHEA or testosterone consistently reduced adiposity, despite which
numerous studies have failed to find proof of any beneficial effect on glucose metabolism.
This study confirmed that administration of DHEA and testosterone reduced body weight and
fat weight equally, as described in our previous study [44]. If this conclusion is applied to men
for weight reduction, supplementation of DHEA would be more desirable than that of
testosterone given the smaller possibility of adverse effects. Our study also reveals that DHEA
and testosterone attenuate proliferation of 3T3-L1 preadipocytes in a similar concentration
dependent manner [44]. In addition, we showed that these hormones decrease the expression
levels of PPARγ, LPL and FABP4, but not SREBP-1, at common concentrations and in a time
dependent manner [44]. The possibility that fat content increased in other organs in compen‐
sation for the decrease in fat mass, was ruled out by the fact that fat content in liver and skeletal
muscle decreased similarly both in DHEA and testosterone-treated rats [44], which was
confirmed in this experiment. The findings that neither DHEA nor testosterone increased
glycerol release in 3T3-L1 adipocytes and administration of these hormones decreased serum
free fatty acid concentration in rats, rule out the possibility that these hormones reduce
adiposity by increased lipolysis [41]. In this study, we revealed that both DHEA and testos‐
terone suppress differentiation of adipocytes using F442A. Both DHEA and testosterone
equivalently inhibited spontaneous differentiation of cells. Recently, concurrent results have
been published with regard to 3T3-L1 preadipocytes, C3H 10T1/2 pluripotent cells and human
preadipocytes [52-55]. Singh et al, reported that formation of androgen receptor/β-catenin and
T-cell factor 4 complex and activation of Wnt signaling are involved in androgen-induced
inhibition of adipogenesis [54].
To clarify the mechanisms underlying androgen-induced weight reduction, we analyzed the
effect of testosterone administration on energy expenditure. Administration of both DHEA
and testosterone increased the rectal temperature in rats [44]. Although an abnormally high
body temperature was not detected, elevated O2 consumption and CO2 production was
observed in testosterone-treated mice (Fig. 4A-D). Although heat production was increased in
testosterone-treated mice, it was not significant when these values were not normalized by
body weight (Fig. 4E). We have no data on lean body mass or water. If lean body mass is not
influenced by testosterone, testosterone-induced reduction of adiposity could not result from
an increase in energy expenditure. On the other hand, our results indicate that basal metabolic
rate increases in testosterone-treated mice since heat production in these mice did not decreas
despite suppressed locomotor activity. The result of suppressed locomotor activity in testos‐
terone-treated mice was unexpected, since lower locomotor activity was also reported in
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ARKO [51]. We are not yet able to explain this discrepancy, probably because change in
locomotor activity may not occur in parallel with an androgen signal.
Next, we speculated that testosterone might increase mitochondrial activity to explain the
increased basal metabolic rate. As shown in Fig. 5A, increased Cox4, a mitochondrial protein,
as well as PGC1α, an up-stream regulator of mitochondrial biogenesis, was recognized in
skeletal muscle isolated from testosterone-treated rats. Similar results were noted in mice [45].
In addition, treatment with testosterone up-regulates the expression levels of genes contribu‐
ting to mitochondrial biogenesis, such as nuclear respiratory factor-1 (NRF-1), NRF-2 and
mitochondrial transcriptional factor A (Tfam), as well as mitochondrial DNA (mitDNA) in
skeletal muscle [44]. Although DHEA and testosterone exhibit similar effects on adipocytes,
administration of DHEA resulted in less increase in Cox4 than that of testosterone in skeletal
muscle. This result was confirmed by the experiment showing that the testosterone-induced
increase in mRNA of PGC1α and cytochrome C was greater than the DHEA-induced ones
(Fig. 5C) in C2C12 myotubes. These results are consistent with data published by Sato et al. [41].
These differences in the response to DHEA and testosterone between adipocytes and myocytes
may be attributable to differences in the efficacy of subcellular steroid converting enzymes.
Although we did not assess the effect of androgens on total skeletal muscle volume, androgens
have been reported to enhance the differentiation into skeletal muscle [53]. Therefore, the
conclusion derived from our experiment should be further explored by increasing the whole
skeletal muscle mass. In addition, we found that expression of PGC1α and mitochondrial genes
was reduced in skeletal muscle isolated from ARKO [45].
The results of our studies were summarized in Fig. 6. DHEA and testosterone equally sup‐
pressed proliferation of preadipocytes, differentiation of adipocytes and expression of
PPARγ and its down-stream genes including adiponectin in adipocytes. Both DHEA and
testosterone up-regulated PGC1α and mitochondrial biogenesis, more actively in the latter
than the former in skeletal muscle. Which organ plays the main role in the androgens-induced
reduction of adiposity remains an interesting problem. Our results suggest that reduced
adiposity in testosterone-treated animals may be derived from decreased expression of
PPARγ and suppressed differentiation into adipocytes. Moderate suppression of PPARγ
activity by its antagonist HX531 resulted in decreased fat mass and increased oxygen con‐
sumption [56], and therefore androgen-induced reduction of PPARγ expression may be able
to influence systemic energy metabolism.
Whole body silencing of AR results in late-onset obesity [51, 56]. Recent technology has
facilitated the generation of organ specific deletion of a gene. Adipocyte specific AR deficient
mice showed identical body weight and adiposity with wild type at 20 wk of age in one study,
although the authors did not show the data of older mice [57]. Since late obesity after 20 wk
of age is the distinguishing feature in ARKO, this point is important. Conversely, mice lacking
AR in the central nervous system develop late onset obesity and insulin resistance [59].
Although several investigations have reported that myocyte specific AR knockdown did not
influence body weight and adiposity [60, 61], myocyte specific AR overexpression resulted in
an increased metabolic rate and fat body mass [62]. These results suggest that skeletal muscle
and brain might be responsible organs for androgen-induced reduction of adiposity. However,
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the role of AR in adipocytes in systemic insulin sensitivity cannot be ruled out at present.
Further experiments will be required to help clarify these issues.
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